Vaccine development for respiratory syncytial virus

Current Opinion in Virology

Volumn 23, Issue , 2017, Pages 107-112

  Graham, Barney S ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RESPIRATORY SYNCYTIAL VIRUS VACCINE; F PROTEIN, HUMAN RESPIRATORY SYNCYTIAL VIRUS; LIVE VACCINE; NEUTRALIZING ANTIBODY; RECOMBINANT VACCINE; VIRUS ANTIBODY; VIRUS FUSION PROTEIN;

EPIDEMIOLOGY; HISTORY; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNITY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; BLOOD; DRUG DEVELOPMENT; IMMUNOLOGY; ISOLATION AND PURIFICATION; RESPIRATORY SYNCYTIAL VIRUS INFECTION; TRENDS;

ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; DRUG DISCOVERY; HUMANS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VIRAL FUSION PROTEINS;

EID: 85019198445     PISSN: 18796257     EISSN: 18796265     Source Type: Journal    
DOI: 10.1016/j.coviro.2017.03.012     Document Type: Review

References (51)

1. Martinez, F.D., Respiratory syncytial virus bronchiolitis and the pathogenesis of childhood asthma. Pediatr. Infect. Dis. J. 22:Suppl. 2 (2003), S76–S82.
2. Glezen, W.P., Taber, L.H., Frank, A.L., Kasel, J.A., Risk of primary infection and reinfection with respiratory syncytial virus. Am. J. Dis. Child. 140 (1986), 543–546.
3. Hall, C.B., Walsh, E.E., Long, C.E., Schnabel, K.C., Immunity to and frequency of reinfection with respiratory syncytial virus. J. Infect. Dis. 163 (1991), 693–698.
4. Falsey, A.R., Hennessey, P.A., Formica, M.A., Cox, C., Walsh, E.E., Respiratory syncytial virus infection in elderly and high-risk adults. N. Engl. J. Med. 352 (2005), 1749–1759.
5. Milner, M.E., de la Monte, S.M., Hutchins, G.M., Fatal respiratory syncytial virus infection in severe combined immunodeficiency syndrome. Am. J. Dis. Child. 139 (1985), 1111–1114.
6. Hertz, M.I., Englund, J.A., Snover, D., Bitterman, P.B., McGlave, P.B., Respiratory syncytial virus-induced acute lung injury in adult patients with bone marrow transplants: a clinical approach and review of the literature. Medicine (Baltimore) 68 (1989), 269–281.
7. Wendt, C.H., Community respiratory viruses: organ transplant recipients. Am. J. Med. 102 (1997), 31–36 discussion 42–43.
8. Zhang, Y., Wang, Y., Gilmore, X., Xu, K., Wyde, P.R., Mbawuike, I.N., An aged mouse model for RSV infection and diminished CD8(+) CTL responses. Exp. Biol. Med. (Maywood) 227 (2002), 133–140.
9. Malloy, A.M., Falsey, A.R., Ruckwardt, T.J., Consequences of immature and senescent immune responses for infection with respiratory syncytial virus. Curr. Top. Microbiol. Immunol. 372 (2013), 211–231.
10. Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380 (2012), 2095–2128.
11. Blount, R.E. Jr, Morris, J.A., Savage, R.E., Recovery of cytopathogenic agent from chimpanzees with coryza. Proc. Soc. Exp. Biol. Med. 92 (1956), 544–549.
12. Parrish, J., Observations on a peculiar catarrhal complaint in children. North Am. Med. Surg. J. 1 (1826), 24–31.
13. Goodpasture, E.W., Auerbach, S.H., Swanson, H.S., Cotter, E.F., Virus pneumonia of infants secondary to epidemic infections. Am. J. Dis. Child. 57 (1939), 997–1011.
14. Adams, J.M., Primary virus pneumonitis in infants. Pediatrics, 1, 1948, 398.
15. Adams, J.M., Primary virus pneumonitis with cystoplasmic inclusion bodies: study of epidemic involving 32 infants with 9 deaths. JAMA, 116, 1941, 9.
16. Bockova, J., O'Brien, K.L., Oski, J., Croll, J., Reid, R., Weatherholtz, R.C., et al. Respiratory syncytial virus infection in Navajo and White Mountain Apache children. Pediatrics, 110(2 Pt. 1), 2002, e20.
17. Karron, R.A., Singleton, R.J., Bulkow, L., Parkinson, A., Kruse, D., DeSmet, I., et al. Severe respiratory syncytial virus disease in Alaska native children. RSV Alaska Study Group. J. Infect. Dis. 180 (1999), 41–49.
18. Kim, H.W., Canchola, J.G., Brandt, C.D., Pyles, G., Chanock, R.M., Jensen, K., et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 89 (1969), 422–434.
19. The IMpact-RSV Study Group, Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 102:3 Pt. 1 (1998), 531–537.
20. Groothuis, J.R., Simoes, E.A., Hemming, V.G., Respiratory syncytial virus (RSV) infection in preterm infants and the protective effects of RSV immune globulin (RSVIG). Respiratory Syncytial Virus Immune Globulin Study Group. Pediatrics 95 (1995), 463–467.
21. O'Brien, K.L., Chandran, A., Weatherholtz, R., Jafri, H.S., Griffin, M.P., Bellamy, T., et al. Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial. Lancet Infect. Dis. 15 (2015), 1398–1408.
22. Morabito, K.M., Ruckwardt, T.R., Redwood, A.J., Moin, S.M., Price, D.A., Graham, B.S., Intranasal administration of RSV antigen-expressing MCMV elicits robust tissue-resident effector and effector memory CD8+ T cells in the lung. Mucosal Immunol. 10 (2017), 545–554.
23. Liu, J., Haddad, E.K., Marceau, J., Morabito, K.M., Rao, S.S., Filali-Mouhim, A., et al. A Numerically subdominant CD8 T cell response to matrix protein of respiratory syncytial virus controls infection with limited immunopathology. PLoS Pathog., 12, 2016, e1005486.
24. Zhang, L., Peeples, M.E., Boucher, R.C., Collins, P.L., Pickles, R.J., Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells, and without obvious cytopathology. J. Virol. 76 (2002), 5654–5666.
25. Johnson, J.E., Gonzales, R.A., Olson, S.J., Wright, P.F., Graham, B.S., The histopathology of fatal untreated human respiratory syncytial virus infection. Mod. Pathol. 20 (2007), 108–119.
26. Hambling, M.H., Survival of the respiratory syncytial virus during storage under various conditions. Br. J. Exp. Pathol. 45 (1964), 647–655.
27. Killikelly, A.M., Kanekiyo, M., Graham, B.S., Pre-fusion F is absent on the surface of formalin-inactivated respiratory syncytial virus. Sci. Rep., 6, 2016, 34108.
28. Ruckwardt, T.J., Morabito, K.M., Graham, B.S., Determinants of early life immune responses to RSV infection. Curr. Opin. Virol. 16 (2016), 151–157.
29. Chiu, C., Openshaw, P.J., Antiviral B cell and T cell immunity in the lungs. Nat. Immunol. 16 (2015), 18–26.
30. Lambert, L., Sagfors, A.M., Openshaw, P.J., Culley, F.J., Immunity to RSV in early-life. Front. Immunol., 5, 2014, 466.
31. Barik, S., Respiratory syncytial virus mechanisms to interfere with type 1 interferons. Curr. Top. Microbiol. Immunol. 372 (2013), 173–191.
32. Johnson, T.R., McLellan, J.S., Graham, B.S., Respiratory syncytial virus glycoprotein G interacts with DC-SIGN and L-SIGN to activate ERK1 and ERK2. J. Virol. 86 (2012), 1339–1347.
33. Bukreyev, A., Yang, L., Fricke, J., Cheng, L., Ward, J.M., Murphy, B.R., et al. The secreted form of respiratory syncytial virus G glycoprotein helps the virus evade antibody-mediated restriction of replication by acting as an antigen decoy and through effects on Fc receptor-bearing leukocytes. J. Virol. 82 (2008), 12191–12204.
34. Griffin, M.P., Khan, A.A., Esser, M.T., Jensen, K., Takas, T., Kankam, M.K., et al. Safety, tolerability, and pharmacokinetics of MEDI8897, the respiratory syncytial virus prefusion F-targeting monoclonal antibody with an extended half-life, in healthy adults. Antimicrob. Agents Chemother., 61, 2017.
35. Ngwuta, J.O., Chen, M., Modjarrad, K., Joyce, M.G., Kanekiyo, M., Kumar, A., et al. Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera. Sci. Transl. Med., 7, 2015 309ra162.
36. Gilman, M.S., Castellanos, C.A., Chen, M., Ngwuta, J.O., Goodwin, E., Moin, S.M., et al. Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors. Sci. Immunol., 1, 2016.
37. Wright, P.F., Karron, R.A., Belshe, R.B., Shi, J.R., Randolph, V.B., Collins, P.L., et al. The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines. Vaccine 25 (2007), 7372–7378.
38. Karron, R.A., Luongo, C., Thumar, B., Loehr, K.M., Englund, J.A., Collins, P.L., et al. A gene deletion that up-regulates viral gene expression yields an attenuated RSV vaccine with improved antibody responses in children. Sci. Transl. Med., 7, 2015 312ra175.
39. Stobart, C.C., Rostad, C.A., Ke, Z., Dillard, R.S., Hampton, C.M., Strauss, J.D., et al. A live RSV vaccine with engineered thermostability is immunogenic in cotton rats despite high attenuation. Nat. Commun., 7, 2016, 13916.
40. Schmidt, A.C., McAuliffe, J.M., Murphy, B.R., Collins, P.L., Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3. J. Virol. 75 (2001), 4594–4603.
41. Liang, B., Surman, S., Amaro-Carambot, E., Kabatova, B., Mackow, N., Lingemann, M., et al. Enhanced neutralizing antibody response induced by respiratory syncytial virus prefusion F protein expressed by a vaccine candidate. J. Virol. 89 (2015), 9499–9510.
42. Liang, B., Ngwuta, J.O., Herbert, R., Swerczek, J., Dorward, D.W., Amaro-Carambot, E., et al. Packaging and prefusion stabilization separately and additively increase the quantity and quality of respiratory syncytial virus (RSV)-neutralizing antibodies induced by an RSV fusion protein expressed by a parainfluenza virus vector. J. Virol. 90 (2016), 10022–10038.
43. Johnson, T.R., Rangel, D., Graham, B.S., Brough, D.E., Gall, J.G., Genetic vaccine for respiratory syncytial virus provides protection without disease potentiation. Mol. Ther. 22 (2014), 196–205.
44. Taylor, G., Thom, M., Capone, S., Pierantoni, A., Guzman, E., Herbert, R., et al. Efficacy of a virus-vectored vaccine against human and bovine respiratory syncytial virus infections. Sci. Transl. Med., 7, 2015 300ra127.
45. Widjojoatmodjo, M.N., Bogaert, L., Meek, B., Zahn, R., Vellinga, J., Custers, J., et al. Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats. Vaccine 33 (2015), 5406–5414.
46. Geall, A.J., Verma, A., Otten, G.R., Shaw, C.A., Hekele, A., Banerjee, K., et al. Nonviral delivery of self-amplifying RNA vaccines. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 14604–14609.
47. Pardi, N., Weissman, D., Nucleoside modified mRNA vaccines for infectious diseases. Methods Mol. Biol. 1499 (2017), 109–121.
48. Langley, J.M., Sales, V., McGeer, A., Guasparini, R., Predy, G., Meekison, W., et al. A dose-ranging study of a subunit respiratory syncytial virus subtype A vaccine with and without aluminum phosphate adjuvantation in adults > or = 65 years of age. Vaccine 27 (2009), 5913–5919.
49. Falsey, A.R., Walsh, E.E., Capellan, J., Gravenstein, S., Zambon, M., Yau, E., et al. Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (RSV) vaccines – nonadjuvanted vaccine or vaccine adjuvanted with alum – given concomitantly with influenza vaccine to high-risk elderly individuals. J. Infect. Dis. 198 (2008), 1317–1326.
50. Cunningham, A.L., Lal, H., Kovac, M., Chlibek, R., Hwang, S.J., Diez-Domingo, J., et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N. Engl. J. Med. 375 (2016), 1019–1032.
51. Miyairi, I., DeVincenzo, J.P., Human genetic factors and respiratory syncytial virus disease severity. Clin. Microbiol. Rev. 21 (2008), 686–703.